Social Media Ideas for Keytruda

Merck after Keytruda: what the pipeline looks like 

Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry. The post Merck after Keytruda: what the pipeline looks like  appe...

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-...

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the supe...

Merck, Moderna report positive Phase 3 melanoma results for Keytruda combination

Rahway-based Merck and Moderna said Aug. 19 that a Phase 3 trial of an investigational mRNA-based cancer therapy used in combination with Keytruda met its primary and key secondary...

Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination

After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before qui...

Merck ADC, in China study, shows potential to replace chemo in lung cancer

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for fro...

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push

Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cance...

GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study

GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has alrea...

Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact

As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use...

<![CDATA[FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma]]>

AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda

AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune...

Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for...

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage tri...

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test

Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the...

Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma

Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a patient’s tumors, met the main goal of a pivotal test...

$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval

GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently a...

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna share...

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrat...

Thousands sign petition seeking Keytruda funding for early-stage breast cancer

The petition which has more than 17,000 signatures asks to expand the eligibility criteria for the cancer drug to those with an early diagnosis.

<![CDATA[Replimune Shares Crash Following FDA Review of Melanoma Treatment]]>

Personalized Vaccine Helped Melanoma Patients Stay Cancer-Free Longer, Drugmakers Say

THURSDAY, Aug. 20, 2026 — An experimental vaccine kept melanoma from returning or spreading in people at high risk of the skin cancer coming back, drugmakers Moderna and Merck anno...

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>